Interview with the Innovators – December 2021

Practical Applications and Clinical Utility of PYLARIFY® (piflufolastat F 18) Injection: An ¹⁸F-PSMA PET/CT Imaging Agent for Prostate Cancer
A series of interviews was recently conducted with a panel of experts on prostate cancer imaging modalities that included Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, and Neal D. Shore, MD, FACS, CMO, Surgical Oncology/Urology Genesis Care, US; Director, CPI, Carolina Urologic Research Center, Myrtle Beach, SC. Read More ›

Dr Doshi and colleagues used the study sample to predict what costs would have been using the MedPAC proposals and found that for patients using specialty RA drugs, the OOP costs would remain front loaded into the beginning of the year, ranging from $512 to $1076 per month from January to May.

Read More ›

The researchers observed that previous studies of dermatologic diseases have shown a much higher prevalence of depression in patients with CLE—in some cases double or triple that of the general population.

Read More ›

As oncologists and oncology practice managers know all too well, the increasing cost of cancer care has created a difficult financial conundrum for many patients with cancer. Yousuf Zafar, MD, MHS, Associate Professor of Medicine, Duke Cancer Institute, was the first to coin the term financial toxicity in the literature. Oncology Practice Management (OPM) asked Dr Zafar for his perspective on this topic. Read More ›

What does a Health Insurance Portability and Accountability Act (HIPAA)-related “incident response” mean to your organization and your oncology practice? Multiple articles and letters have been written on the subject, and the one thing that almost every author agrees on is that incident response must be a team approach: it must be embraced by the top, and permeate throughout the rest of any organization for it to work. Read More ›

As the trend of shifting the site of infusion services from the physician office to the hospital outpatient department continues, so does the conversation about the revenue differences in doing so. Read More ›

Patients who have not had meaningful discussions with clinicians about end-of-life care—including chemotherapy, cardiopulmonary resuscitation, and referral for hospice care—have an increased likelihood of receiving inappropriate, aggressive care at the end of life. Read More ›

In an effort to contain healthcare costs and to improve the quality of cancer care via shared decision-making, the ASCO Value in Cancer Care Task Force developed a conceptual framework to assess the value of new cancer drugs versus current standard-of-care treatments in 2 clinical settings: advanced disease and potentially curative disease. Read More ›

Think back to a time when you had a bad work experience or left a job. What happened that made you miserable or made you leave? Of course, pay is important, as are other logistical items such as commute time and flexible work schedules for family obligations. But, when we say an employee has “left the company,” most likely it was because of a manager. Read More ›

Urology Practice Management logo
Subscribe to Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.

UPM e-Newsletter
UPM print publication